Highly motivated and detail-oriented Biology graduate from Prairie View A&M University with a strong foundation in laboratory research, data analysis, and scientific inquiry. Recognized on the Dean’s List for six semesters and certified in biosafety and research ethics. Experienced in academic research, molecular techniques, and collaborative projects. Passionate about contributing to biomedical and clinical research efforts that improve health outcomes.
Antibacterial Effects of Plant-Based Extracts on Multi-Drug Resistant Bacteria:
Investigated antimicrobial properties of herbal extracts against E. coli and S. aureus
Prepared and standardized extract concentrations
Recorded and interpreted inhibition zones
Presented findings at Undergraduate Research Symposium
PRNP Gene: Decoding the Genetics of Fatal Familial Insomnia
Identify and characterize mutations in the PRNP gene that lead to Fatal Familial Insomnia (FFI)
• Investigate the molecular and structural role of prion protein (PrP) in the disease process
• Utilize bioinformatics tools and databases to explore genetic variants, pathways, and protein interactions
• Determine which biological processes and pathways are affected by PRNP gene mutations
In Vivo Fate and Activity of Second vs Third Generation CD19- Specific CAR- T cells in B cells Non-Hodgkin's Lymphomas
Compare the effectiveness of second-generation (2G) CAR-T cells (with CD28) versus third-generation (3G) CAR-T cells (with CD28 + 4-1BB) in treating relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).
Evaluate in vivo activity, including:
• Expansion
• Persistence
• Molecular signals of the CAR-T cells over time
Assess clinical outcomes in patients infused with both CAR-T cell types:
• Response rates (Complete Response, Partial Response, Stable Disease, Non-Response)
• Duration of remission
• Survival outcomes
Determine safety profiles, focusing on:
• Cytokine Release Syndrome (CRS)
• Other adverse effects
Explore the impact of disease status:
• Compare outcomes in patients with active disease vs. those post-autologous stem cell transplant (ASCT).
Identify whether third-generation CAR-T cells offer meaningful advantages over second-generation cells in terms of therapeutic durability and tolerability.
Oligodendrocyte Dysfunction in Multiple Sclerosis